What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Linzagolix demonstrated moderate benefit over placebo in treating moderate to severe symptoms of uterine fibroids, with significant improvements in primary outcomes such as menstrual blood loss reduction. However, it has not been directly compared with the relevant comparator, relugolix combination therapy, which limits the strength of the evidence.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness analysis indicated that linzagolix is cost-effective for longer-term treatment, with an ICER of £5,524 per QALY gained, which is well below the acceptable threshold of £20,000. This suggests a strong economic value for the treatment in the appropriate patient population.
Is there quality-of-life evidence payers weigh? — Quality of life
The clinical trials included quality of life assessments using the UFS-QoL and EQ-5D-5L instruments, showing moderate improvements in quality of life for patients treated with linzagolix. However, the evidence is somewhat limited by the reliance on disease-specific measures rather than the more general EQ-5D.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Linzagolix has an acceptable safety profile, with most adverse events being mild to moderate. Serious adverse events were similar across treatment arms, and while there was some reduction in bone mineral density, it was not clinically meaningful, indicating manageable safety concerns.
Was the drug compared against what payers expect? — Comparator Selection
The evidence primarily compares linzagolix to placebo, with indirect comparisons to relugolix CT. The absence of direct head-to-head trials with all relevant comparators, particularly GnRH agonists, raises concerns about the robustness of the comparator selection.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial populations were broadly representative of those with moderate to severe symptoms of uterine fibroids, with consideration of various subgroups. However, the exclusion of certain populations needing urgent treatment limits generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Linzagolix can be integrated into existing treatment pathways with minor adjustments, as it offers flexibility in dosing and can be used with or without hormonal add-back therapy, aligning well with current clinical practices.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic analysis indicates that linzagolix has a manageable budget impact, with the potential for cost savings in the longer term. The resource use model was deemed appropriate for decision-making.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on two well-structured RCTs (PRIMROSE 1 and 2) with low bias risk. However, the reliance on indirect comparisons introduces some uncertainty regarding the robustness of the findings.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the indirect treatment comparisons and the generalizability of the trial populations to the broader patient population. This uncertainty may impact the overall confidence in the cost-effectiveness estimates.
